John Yarnold
The Royal Marsden NHS Foundation Trust
CancerInternal medicineRadiologySurgeryPathologyOncologyRandomized controlled trialMedical physicsAdverse effectChemotherapyMastectomyRegimenBreast radiotherapyNuclear medicineNormal tissueEarly breast cancerRadiation therapyBreast cancerClinical trialMedicine
337Publications
71H-index
13kCitations
Publications 335
Newest
#1A.M. Brunt (Keele University)H-Index: 12
#1A.M. Brunt (ICR: Institute of Cancer Research)H-Index: 2
Last. John YarnoldH-Index: 71
view all 7 authors...
Abstract Introduction The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in relation to implementing this schedule. Ipsilateral Breast Tumour Relapse (IBTR) Published estimated 5-year IBTR with 95% CI after 40 Gy in 15 fractions was 2.1% (95% CI 1.4–3.1), 1.7% (1.2–1.6) after 27 Gy and 1.4% (0.2–2.2) after 26 Gy, emphat...
Source
#1Selvakumar Anbalagan (ICR: Institute of Cancer Research)H-Index: 1
#2Cecilia Ström (ICR: Institute of Cancer Research)
Last. Navita Somaiah (ICR: Institute of Cancer Research)H-Index: 12
view all 10 authors...
Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient basis. Understanding cell and molecular mechanisms determining fraction size sensitivity is essential to fully exploit this therapeutic variable for patient benefit. The hypothesis under test in this study is that fraction size sensitivity is dependent on the presence of wild...
Source
#1A.M. Brunt (Keele University)H-Index: 12
#2Joanne S HavilandH-Index: 27
Last. John YarnoldH-Index: 71
view all 4 authors...
Source
#1A.M. BruntH-Index: 2
#2Joanne S HavilandH-Index: 27
Last. John YarnoldH-Index: 71
view all 25 authors...
Source
#1Søren M. Bentzen (UMB: University of Maryland, Baltimore)H-Index: 102
#2Joanne S Haviland (ICR: Institute of Cancer Research)H-Index: 27
Last. John Yarnold (The Royal Marsden NHS Foundation Trust)H-Index: 71
view all 3 authors...
1 CitationsSource
#1A.M. Brunt (University Hospitals of North Midlands NHS Trust)H-Index: 12
#1A.M. Brunt (University Hospitals of North Midlands NHS Trust)H-Index: 2
Last. John Yarnold (The Royal Marsden NHS Foundation Trust)H-Index: 71
view all 26 authors...
PURPOSEPrevious studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evalu...
17 CitationsSource
#1Samantha Nimalasena (ICR: Institute of Cancer Research)H-Index: 1
#2Lone Gothard (ICR: Institute of Cancer Research)H-Index: 15
Last. Navita Somaiah (The Royal Marsden NHS Foundation Trust)H-Index: 12
view all 24 authors...
Abstract Purpose Hydrogen peroxide (H2O2) plays a vital role in normal cellular processes but at supraphysiological concentrations causes oxidative stress and cytotoxicity, a property that is potentially exploitable for the treatment of cancer in combination with radiotherapy (RT). We report the first Phase I trial testing the safety and tolerability of intratumoural H2O2 + external beam RT as a novel combination in patients with breast cancer, and exploratory plasma marker analyses investigatin...
2 CitationsSource
#1A.M. Brunt (Keele University)H-Index: 12
#2Joanne S Haviland (ICR: Institute of Cancer Research)H-Index: 27
Last. John R Yarnold (The Royal Marsden NHS Foundation Trust)H-Index: 1
view all 46 authors...
Summary Background We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results of the FAST-Forward trial. Methods FAST-Forward is a multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 radiotherapy centres and 50 referring h...
103 CitationsSource
#1A Murray Brunt (Government of the United Kingdom)H-Index: 6
#2Joanne S Haviland (ICR: Institute of Cancer Research)H-Index: 27
Last. John Yarnold (ICR: Institute of Cancer Research)H-Index: 71
view all 23 authors...
Background: FAST-Forward aims to identify a 5-fraction (Fr) schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week which is non-inferior for local cancer control and as safe as an international standard 15Fr regimen after primary surgery for early breast cancer. Five-year results are presented. Methods: FAST-Forward (ISRCTN19906132) randomised (1:1:1) patients with invasive carcinoma of the breast (pT1-3 pN0-1 M0) after breast conservation surgery or mastectomy to 40Gy in 15Fr...
Source
#1A. Kurup (Imperial College London)H-Index: 36
#2Jaroslaw Pasternak (Imperial College London)H-Index: 16
Last. John Yarnold (ICR: Institute of Cancer Research)H-Index: 71
view all 15 authors...
Abstract The Centre for the Clinical Application of Particles’ Laser-hybrid Accelerator for Radiobiological Applications (LhARA) facility is being studied and requires simulation of novel accelerator components (such as the Gabor lens capture system), detector simulation and simulation of the ion beam interaction with cells. The first stage of LhARA will provide protons up to 15 MeV for in vitro studies. The second stage of LhARA will use a fixed-field accelerator to increase the energy of the p...
4 CitationsSource